Cutaneous Tumor
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
Topical Anaesthesia in Cutaneous Head and Neck Surgery
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study